Literature DB >> 20430463

Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer.

Yukinori Matsuo1, Yuji Nakamoto, Yasushi Nagata, Keiko Shibuya, Kenji Takayama, Yoshiki Norihisa, Masaru Narabayashi, Takashi Mizowaki, Tsuneo Saga, Tatsuya Higashi, Kaori Togashi, Masahiro Hiraoka.   

Abstract

BACKGROUND AND
PURPOSE: The purpose was to characterize (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) findings after stereotactic body radiation therapy (SBRT) for lung cancer.
MATERIALS AND METHODS: This was a retrospective review of 32 FDG-PET scans from 23 patients who underwent SBRT for lung cancer and who showed no evidence of local recurrence. The FDG uptake by lesions was assessed visually using a 3-point scale (0, none or faint; 1, mild; or 2, moderate to intense), and the demarcation (ill- or well-defined) was evaluated. For semi-quantitative analysis, the maximum standardized uptake value (SUVmax) was calculated.
RESULTS: Grade 2 intensity was observed in 70%, 33%, 30%, and 0% of PET scans performed <6, 6-12, 12-24, and >24 months, respectively, after SBRT; well-defined demarcation was observed in 80%, 33%, 40%, and 17%, respectively, and the respective means of the SUVmax were 4.9, 2.6, 3.0, and 2.3. The SUVmax was significantly higher for scans performed at <6 months than at 6-12 or >24 months.
CONCLUSIONS: FDG uptake tended to be intense and well-defined at early times after SBRT, especially within 6 months, and was faint and ill-defined at later periods. Moderate to intense FDG uptake observed soon after SBRT does not always indicate a residual tumour.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20430463     DOI: 10.1016/j.radonc.2010.04.011

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  21 in total

Review 1.  New techniques for assessing response after hypofractionated radiotherapy for lung cancer.

Authors:  Sarah A Mattonen; Kitty Huang; Aaron D Ward; Suresh Senan; David A Palma
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

Review 2.  Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?

Authors:  Sarah A Mattonen; Aaron D Ward; David A Palma
Journal:  Br J Radiol       Date:  2016-06-20       Impact factor: 3.039

3.  Stereotactic ablative radiotherapy for stage I NSCLC: Recent advances and controversies.

Authors:  Suresh Senan; David A Palma; Frank J Lagerwaard
Journal:  J Thorac Dis       Date:  2011-09       Impact factor: 2.895

4.  Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer.

Authors:  Wouter van Elmpt; Michel Ollers; Anne-Marie C Dingemans; Philippe Lambin; Dirk De Ruysscher
Journal:  J Nucl Med       Date:  2012-08-09       Impact factor: 10.057

5.  Computed tomographic features predictive of local recurrence in patients with early stage lung cancer treated with stereotactic body radiation therapy.

Authors:  Darragh Halpenny; Carole A Ridge; Sara Hayes; Junting Zheng; Chaya S Moskowitz; Andreas Rimner; Michelle S Ginsberg
Journal:  Clin Imaging       Date:  2014-12-12       Impact factor: 1.605

6.  Illustrative cases of false positive biopsies after stereotactic body radiation therapy for lung cancer based on abnormal FDG-PET-CT imaging.

Authors:  Mamta Singhvi; Percy Lee
Journal:  BMJ Case Rep       Date:  2013-01-22

7.  Circulating Tumor Cell Assessment in Presumed Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Prospective Pilot Study.

Authors:  Melissa A Frick; Gary D Kao; Louise Aguarin; Chimbu Chinniah; Samuel Swisher-McClure; Abigail T Berman; William P Levin; Keith A Cengel; Cristina DeCesaris; Stephen M Hahn; Jay F Dorsey; Charles B Simone
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-07-02       Impact factor: 7.038

8.  Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer.

Authors:  Xu Zhang; Hui Liu; Peter Balter; Pamela K Allen; Ritsuko Komaki; Tinsu Pan; Hubert H Chuang; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-07       Impact factor: 7.038

9.  Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.

Authors:  Joe Y Chang; Hui Liu; Peter Balter; Ritsuko Komaki; Zhongxing Liao; James Welsh; Reza J Mehran; Jack A Roth; Stephen G Swisher
Journal:  Radiat Oncol       Date:  2012-09-10       Impact factor: 3.481

10.  Scalpel or SABR for Treatment of Early-Stage Lung Cancer: Clinical Considerations for the Multidisciplinary Team.

Authors:  Shervin M Shirvani; Joe Y Chang
Journal:  Cancers (Basel)       Date:  2011-09-01       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.